SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunicum - ilixadencel in MERECA Phase II - results soon !
IMMU.ST 10.06-1.1%4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: loparn8/29/2019 5:28:38 AM
   of 17
 
"Immunicum AB (publ) Announces Positive Phase II MERECA Topline Results Including Complete Tumor Responses in Metastatic Renal Cell Carcinoma Patients

Press Release

29 August 2019

Immunicum AB (publ) Announces Positive Phase II MERECA Topline Results Including Complete Tumor Responses in Metastatic Renal Cell Carcinoma Patients

--Ilixadencel in combination with Sutent® (sunitinib) achieved complete tumor responses in 5 out of 45 evaluable metastatic kidney cancer patients (11%) in contrast to 1 out of 25 in the sunitinib monotherapy control arm (4%)—"

Read more here :

immunicum.se

The market got sour due to unclear survival data after 18 months, which though can be partly explained by a smaller percentage of high risk patients compared to the earlier Phase I/II mRCC studie. We will have to wait for final MOS results several years I guess. The complete respons rate of 11 % is promising so the market has probably overreacted. The financial position is still strong with capital lasting to the end of 2021 and the ongoing ILIAD study will be important where ilixadencel is combined with checkpoint inhibitors i 3 big cancer indications.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext